September 5, 2017 / 8:50 PM / 16 days ago

BRIEF-Macrogenics advances two clinical DART molecules

Sept 5 (Reuters) - Macrogenics Inc

* Macrogenics advances two first-in-class clinical DART molecules

* Macrogenics Inc - ‍Macrogenics retains worldwide rights to both of product candidates​

* Macrogenics Inc - ‍under exercised option, funding of up to $10.8 million is available to Macrogenics for these development efforts​

* Macrogenics Inc - ‍second option, if later exercised by Niaid, would provide up to an additional $6.3 million​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below